NCT04808115View on ClinicalTrials.gov

IIT PH1 KDS-1001 in Patients With CML

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
CML (Chronic Myelogenous Leukemia
Interventions
DRUG

KDS-1001

"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Kiadis Pharma
All Listed Sponsors
collaborator

Kiadis Pharma

INDUSTRY

lead

Duke University

OTHER

NCT04808115 - IIT PH1 KDS-1001 in Patients With CML | Biotech Hunter | Biotech Hunter